Providence, RI, Sept. 28, 2023 (GLOBE NEWSWIRE) — Signati Medical™ is pleased to announce the issue of US patent 11,723,680 covering critical features of the bipolar handpiece used in Signati’s Sealed Vasectomy Procedure (SVP)™.
The handpiece patent and the vasectomy method patents expire in 2039. An additional method patent with expanded coverage is pending.
Signati’s patent portfolio also includes patents covering the current Sealed Vasectomy method (8,561,615, expiring November 5, 2027) and an alternate handpiece design (8,220,464, expiring March 12, 2031). Additionally, the jaw configuration of Signati’s handpiece and the two clamp configurations are covered by design patents D903867, D950055, and D886297 respectively, expiring in 2035 and 2037.
About Signati Medical
Signati™ Medical, Inc. is a medical device company that endeavors to take vasectomy to a new level of comfort, safety, and speed. A medical device company dedicated to advancing men’s health, Signati plans to launch the first innovation in vasectomy in more than 20 years with a procedure that would be fast for physicians and comfortable for patients. The Signati Sealed Vasectomy Procedure (SVP)™, designed to take just minutes, could be done right in the urologist’s office and would offer advantages for patients including easier recovery compared to some current vasectomy techniques.
To learn more, visit www.signatimed.com.
Not approved by the Food and Drug Administration (FDA). These statements and the subject product have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. The device is not currently being marketed, nor is it available for sale in any country.
CONTACT: William Prentice President & CEO, Signati Medical Inc. 128 Dorrance Street 6th Floor Providence, RI 02903 william.prentice@signatimed.com
TAIPEI, June 22, 2024 /PRNewswire/ -- The prestigious 2024 Tang Prize Laureates have been announced,…
Afrezza® Afrezza® (insulin human) Inhalation Powder. Study proves inhaled insulin is as effective as usual…
PURCHASE, NY, June 21, 2024 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader…
TERN-501 significantly improved the efficacy of a GLP-1 receptor agonist by normalizing energy expenditure, resulting…
MINNEAPOLIS, June 21, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the…
Shrivers Hospice sets a benchmark for quality care in Ohio with prestigious award LOS ANGELES,…